

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058277 A1

(51) International Patent Classification⁷: **A61K 9/08**,
31/4439, 47/18

(21) International Application Number:
PCT/JP2004/018956

(22) International Filing Date:
13 December 2004 (13.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2003-419288 17 December 2003 (17.12.2003) JP

(71) Applicant (*for all designated States except US*): **TAKEDA
PHARMACEUTICAL COMPANY LIMITED** [JP/JP];
1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka
5410045 (JP).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DOEN, Takayuki**
[JP/JP]; 4-10-803, Senriyamatakatsuka, Suita-shi, Osaka
5650848 (JP). **INOUE, Tomoko** [JP/JP]; 4-713, Suehiro-
cho, Ibaraki-shi, Osaka 5670821 (JP).

(74) Agents: **KAWAMIYA, Osamu** et al.; Aoyama & Partners,
IMP Building, 3-7, Shiromi 1-chome, Chuo-ku, Osaka-shi,
Osaka 5400001 (JP).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: INJECTABLE COMPOSITION

(57) Abstract: An injectable composition comprising a combination of 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole (lansoprazole), its optically active compound or a salt thereof, and a chelating agent, which is used at pH 9 to 12. The injectable composition is excellent in stability and solubility, and has such a high-quality that particulate insolubles are not formed when the composition is kept and supplied in a glass container and even in a plastic container and also when the composition is kept in these container for a long time.

WO 2005/058277 A1